At-211 is a highly promising radioisotope currently being investigated for its potential in targeted alpha-therapies in oncology. Framatome and IBA are seeking to build a network of specialised alpha-emitting cyclotrons, further establishing radio-theranostics, which combines molecular imaging with targeted radionuclide therapy, as a cornerstone of precision oncology.
The first step will be the establishment of a dedicated production pilot facility by 2027-2028 in the Pays de la Loire region in France. Framatome will make a financial investment in the partnership, with IBA contributing equipment. This facility will inform the development of a global network of latest generation alpha-emitting cyclotrons across Europe and the US to meet the growing demand for At-211.
“This partnership with IBA is a significant step toward transforming cancer care through targeted alpha therapy,” said François Gauché, Vice President of Framatome Healthcare. “The secure, scalable, and timely supply of astatine-211 is vital for addressing unmet medical needs, and we are committed to building a robust production network to serve the growing demand. Together, we will provide cancer researchers and patients with access to cutting-edge therapeutic solutions while creating a sustainable foundation for future growth.”
Charles Kumps, President of IBA RadioPharma Solutions said this was the start of a strong partnership. “By leveraging our combined expertise in cyclotron technology and in nuclear medicine, we are creating the critical infrastructure necessary to unlock the full potential of these groundbreaking therapies.”
Framatome’s proprietary isotope production technology enabled the first large-scale commercial production of the radioisotope lutetium-177 in a power reactor in June 2022, enabling reliable and large-scale access to this medical radioisotope. IBA, through its joint venture PanTera, has been advancing actinium-225 production, another key isotope in targeted alpha therapy.
